CSBio CSBio

X
[{"orgOrder":0,"company":"Beactica","sponsor":"Oscotec","pharmaFlowCategory":"D","amount":"$17.8 million","upfrontCash":"Undisclosed","newsHeadline":"Oscotec and Beactica Therapeutics Announce License and Collaboration Agreement to Develop New Cancer Drug","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"SWEDEN","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Beactica"},{"orgOrder":0,"company":"Beactica","sponsor":"Dong-A ST Co., Ltd.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dong-A ST and Beactica Therapeutics Mutually Agree to Conclude Oncology Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"SWEDEN","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Beactica"},{"orgOrder":0,"company":"Simris Group","sponsor":"Lonza Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Simris Alg ab Signs Partnership Agreement With Lonza Ltd to Promote Its ADC Payload Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Simris Group"},{"orgOrder":0,"company":"Anocca","sponsor":"AMF","pharmaFlowCategory":"D","amount":"$36.5 million","upfrontCash":"Undisclosed","newsHeadline":"Anocca Raises SEK 400 Million for Large-Scale Development of Cancer Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"SWEDEN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Anocca"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The financing will develop the company's unique process that enables discovery and manufacture of next generation TCR-T-based cell therapies for cancer on an industrial scale. The financing also allows Anocca to progress the company's first products into clinical trials.

            Lead Product(s): TCR-T-based Therapy

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: AMF

            Deal Size: $36.5 million Upfront Cash: Undisclosed

            Deal Type: Financing May 31, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Lonza will integrate Simris’ antibody-drug conjugate payload technology into the Lonza Bioconjugation Toolbox and will gain the exclusive right to offer the technology to new and existing customers seeking novel payloads to develop into ADC medicines.

            Lead Product(s): Antibody-Drug Conjugate

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: Lonza Group

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration March 10, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            As part of the termination, both Dong-A ST and Beactica Therapeutics will gain exclusive global rights for further development and commercialization for different compounds series developed during the collaboration.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: Dong-A ST Co., Ltd.

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Termination September 06, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the terms of the agreement, Oscotec is entitled to gain exclusive global rights for further development and commercialization of Beactica's programme.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: Oscotec

            Deal Size: $17.8 million Upfront Cash: Undisclosed

            Deal Type: Collaboration March 02, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY